Phase Ib Study: Venetoclax With or Without Azacitidine for Treatment of Relapsed/Refractory Myelodysplastic Syndrome

December 7-10, 2019; Orlando, Florida
Venetoclax alone or in combination with azacitidine was well tolerated in patients with relapsed/refractory MDS, with combination therapy achieving an ORR of 40% and estimated 12-month OS of 65%.
Format: Microsoft PowerPoint (.ppt)
File Size: 236 KB
Released: December 19, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Downloadable slides from a Clinical Care Options (CCO) video on treatment strategies for patients with lower risk myelodysplastic syndrome (MDS)

Rami S. Komrokji, MD Released: January 15, 2021

Read expert answers to clinician questions on optimizing the care of patients with CLL in today’s practice, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Susan M. O'Brien, MD John Pagel Headshot John Pagel, MD, PhD Released: January 15, 2021

Brief expert video from Clinical Care Options (CCO) on recommended treatment strategies for patients with lower-risk myelodysplastic syndrome (MDS)

Rami S. Komrokji, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 15, 2021 Expired: January 14, 2022

Expert answers to clinician questions on current challenges in managing patients with myelodysplastic syndromes (MDS), from Clinical Care Options (CCO)

Guillermo Garcia-Manero, MD Rami S. Komrokji, MD Jamile Shammo, MD, FASCP, FACP Released: January 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue